To sum up, phase II showed that vemurafenib induced clinical response in more than 50% of patients with previously treated metastatic melanoma with BRAF V600 mutation and the follow-up revealed the overall survival of approximately 16 months. This evidence concerns the gene BRAF and metastatic melanoma.